Skip to main content
SpringerLink
Log in

Insulin Aspart

Asp-B28, NovoRapid™

  • Section 1: Type 2 Diabete Mellitus
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Heinemann L, Kapitza C, Starke AAR, et al. Duration of action of the insulin analogue B28Asp in comparison to regular insulin. Diabetes 1996 May; 45 Suppl. 2: 139

    Google Scholar 

  2. Kang S, Brange J, Burch A, et al. Absorption kinetics and action profiles of subcutaneously administered insulin analogues (AspB9GluB27, AspB10, AspB28) in healthy subjects. Diabetes Care 1991 Nov; 14: 1057–65

    Article  PubMed  CAS  Google Scholar 

  3. Barriocanal LA, Ahmed AME, Olsen K, et al. Estimation of the absorption rate and bioavailability of insulin analogue B28- ASP and human unmodified insulin. Diabet Med 1997 Apr; 14 Suppl. 1: 2

    Google Scholar 

  4. Kang S, Brange J, Burch A, et al. Subcutaneous insulin absorption explained by insulin’s physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 1991 Nov; 14: 942–8

    Article  PubMed  CAS  Google Scholar 

  5. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999 May; 55: 199–203

    Article  PubMed  CAS  Google Scholar 

  6. Lindholm A, McEwen J, Riis A. Significantly improved postprandial glycaemic controlwith the novel rapid-acting insulin aspart. Diabetologia 1998 Aug; 41 Suppl. 1: 49

    Google Scholar 

  7. Jacobsen LV, Sogaard B, Riis A. Comparison of the pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart and a similar premix of human insulin. Diabetes 1999 May; 48 Suppl. 1: 108

    Google Scholar 

  8. Mortensen H, Olsen B, Lindhom A. Pharmacokinetics of a rapid-acting human insulin analogue, insulin aspart, in children and adolescents with type 1 diabetes. Diabetes 1999 May; 48 Suppl. 1: 358

    Google Scholar 

  9. Heinemann L, Weyer C, Rauhaus M, et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998 Nov; 21: 1910–4

    Article  PubMed  CAS  Google Scholar 

  10. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999 May; 22: 801–5

    Article  PubMed  CAS  Google Scholar 

  11. Home PD, Lindholm A, Hylleberg B, et al. Improved glycemic control with insulin aspart: a multicenter randomized doubleblind crossover trial in type 1 diabetic patients. Diabetes Care 1998 Nov; 21: 1904–9

    Article  PubMed  CAS  Google Scholar 

  12. Volund A, Brange J, Drejer K, et al. In vitro and in vivo potency of insulin analogues designed for clinical use. Diabet Med 1991 Nov; 8: 839–47

    Article  PubMed  CAS  Google Scholar 

  13. Heinemann L, Heise T, Jorgensen LN, et al. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med 1993 Jul; 10: 535–9

    Article  PubMed  CAS  Google Scholar 

  14. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation: pharmacodynamic properties of a rapidacting insulin analog in stable mixture. Diabetes Care 1997 Oct; 20: 1612–4

    Article  PubMed  CAS  Google Scholar 

  15. Rosenfalck AM, Thorsby P, Kjems L, et al. Effects of the rapidacting insulin analoque insulin Aspart on postprandial glycaemic excursions compared to human soluble insulin Actrapid given immediately or 30 min before ameal in insulin treated type 2 diabetes patients. Diabetes 1999 May; 48 Suppl. 1: 116

    Google Scholar 

  16. Raskin P, McGill J, Kilo C, et al. Human insulin analog (insulin aspart) is comparable to human insulin in type 2 diabetes. Diabetes 1999 May; 48 Suppl. 1: 355

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Insulin Aspart. Drugs R&D 2, 103–106 (1999). https://doi.org/10.2165/00126839-199902020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902020-00004

Keywords

Search

Navigation